Progenics Pharma Reduces 26% Of Workforce - Quick Facts

Trade PGNX now with

9/20/2012 5:35 PM ET

Progenics Pharmaceuticals Inc. (PGNX: Quote) announced a companywide restructuring, including a reduction of its workforce. Headcount was reduced by 26% to 77 employees. Annual cash expenditures will be reduced by an estimated $8 million after restructuring and severance costs, the company said.

The company said it will continue to focus its resources and efforts on its oncology programs, particularly an upcoming phase 2 study of PSMA ADC in prostate cancer patients.

As part of the restructuring, Chief Financial Officer Robert McKinney and Senior Vice President of Quality Benedict Osorio are stepping down, effective September 30. Senior Executive Director and Treasurer Angelo Lovallo will become Principal Financial Officer and Principal Accounting Officer, the company said.

The company said it is terminating several early stage research projects. Preclinical research will continue in the company's PI3K program. Clinical development and manufacturing capabilities are unaffected by the reduction.

The company noted that workforce reduction reflects termination of the early stage research, last year's out-licensing of Relistor to Salix Pharmaceuticals and planned divestitures of the previously discontinued PRO 140 and C. difficile programs.

The company stated that the actions followed the U.S. Food and Drug Administration's issuance of a Complete Response Letter related to a Supplemental New Drug Application for use of subcutaneous Relistor in patients with chronic, non-cancer pain.

Under the terms of its agreement with partner Salix Pharmaceuticals, Progenics is entitled to a $40 million milestone upon regulatory approval of Relistor for this indication.

To receive FREE breaking news email alerts for Progenics Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 117 Articles Next>>

Editors Pick

Stocks Seeing Modest Weakness In Early Trading - U.S. Commentary

Stocks have moved modestly lower in early trading on Wednesday, giving back some ground after closing higher in the two previous sessions. The major averages have dipped into negative territory, although selling pressure remains subdued. The major averages have edged up off their lows for the young session in the past few minutes but remain in the red.

Angelina Jolie Listens To Tragic Stories Of Syrians Fleeing Conflict

Along a dirt track on an unexpectedly cool and windy night on Jordan's border with Syria, as shadows lengthened across the barren hills, UNHCR Special Envoy Angelina Jolie listened to the stories of men, women and children who had fled Syria just hours before. She heard stories of bombs and pain and loss from people fleeing Homs, Dara'a and Qusair, three of the communities devastated by the Sy

King Loses Final Call For QE

Outgoing Bank of England Governor Mervyn King was outvoted in his final policy meeting, as most policymakers overturned his call for additional stimulus citing sustained economic recovery, the minutes of the session held on June 5 and 6 showed Wednesday. As seen in the past few months, King, Paul Fisher and David Miles sought an increase in quantitative easing by GBP 25 billion.